Market closed
Cardiff Oncology/$CRDF
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cardiff Oncology
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
Ticker
$CRDF
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
33
Website
Cardiff Oncology Metrics
BasicAdvanced
$190M
-
-$0.95
1.73
-
Price and volume
Market cap
$190M
Beta
1.73
52-week high
$5.64
52-week low
$2.01
Average daily volume
1.4M
Financial strength
Current ratio
7.079
Quick ratio
6.92
Long term debt to equity
0.98
Total debt to equity
1.836
Management effectiveness
Return on assets (TTM)
-34.01%
Return on equity (TTM)
-59.51%
Valuation
Price to revenue (TTM)
198.842
Price to book
2.29
Price to tangible book (TTM)
2.29
Price to free cash flow (TTM)
-3.595
Growth
Revenue change (TTM)
39.96%
Earnings per share change (TTM)
2.78%
3-year revenue growth (CAGR)
23.91%
3-year earnings per share growth (CAGR)
9.56%
What the Analysts think about Cardiff Oncology
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Cardiff Oncology stock.
Cardiff Oncology Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Cardiff Oncology Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Cardiff Oncology News
AllArticlesVideos
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·4 days ago
Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer
GlobeNewsWire·4 days ago
Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cardiff Oncology stock?
Cardiff Oncology (CRDF) has a market cap of $190M as of April 20, 2025.
What is the P/E ratio for Cardiff Oncology stock?
The price to earnings (P/E) ratio for Cardiff Oncology (CRDF) stock is 0 as of April 20, 2025.
Does Cardiff Oncology stock pay dividends?
No, Cardiff Oncology (CRDF) stock does not pay dividends to its shareholders as of April 20, 2025.
When is the next Cardiff Oncology dividend payment date?
Cardiff Oncology (CRDF) stock does not pay dividends to its shareholders.
What is the beta indicator for Cardiff Oncology?
Cardiff Oncology (CRDF) has a beta rating of 1.73. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.